In an effort to fully leverage the potential of tissue engineering and organoid-based technologies while promoting innovative strategies, the Faculty of Medicine of the University of Geneva established in Q4 2024 the Tissue Engineering & Organoid (TEO) Technology at the Centre Médical Universitaire (CMU). This platform serves as a hub for translational bioengineering expertise, offering consulting services, research and development, and instrumental support for fundamental research initiatives.

With a strong focus on clinical impact, TEO bridges academic research at UniGE with clinical innovation at the Geneva University Hospitals (HUG), working in close partnership with the Laboratories of Cell Therapies and Transplantation (LTC). Together, they develop and accelerate new technologies toward clinical application.

TEO Technology Platform has the mission to:

• Provide dedicated space and tailored services for organoid-based research and technological innovation.
• Support the design of optimized preclinical testing strategies.
• Facilitate and accelerate the clinical translation of novel biomedical technologies and therapies.

Program

• Welcome and introduction of TEO platform, Dr Marisa Jaconi, Faculty of Medicine, UniGE.
• Engineering the Future: Harnessing Organoids for Diabetes Therapy, Prof Ekaterine Berishvili, Laboratory of Tissue Engineering and Organ Regeneration, UniGE.
• NeuroNA Human Cellular Neuroscience Platform : bespoke highend services, Dr. Théo Ribierre, NeuroNA Human Cellular Neuroscience Platform (HCNP).
• GMP Cell Therapy Lab at Geneva University Hospital: bridging translational research, Dr Mathieu Armanet, Clinical Cell Therapy (LTCC), Geneva University Hospitals.
• Functional assessements of human cardioids to model heart development, Dr Marisa Jaconi, Dept. Basic Neurosciences, UniGE.
• Lunch and lab tours